Zacks Research Brokers Raise Earnings Estimates for ResMed

ResMed Inc. (NYSE:RMD) – Investment analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for shares of ResMed in a report issued on Wednesday, January 29th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings of $2.27 per share for the quarter, up from their prior forecast of $2.26. The consensus estimate for ResMed’s current full-year earnings is $9.35 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.30 EPS, Q4 2025 earnings at $2.37 EPS, FY2025 earnings at $9.13 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.49 EPS, Q4 2026 earnings at $2.49 EPS, FY2026 earnings at $9.58 EPS, Q2 2027 earnings at $2.57 EPS and FY2027 earnings at $10.50 EPS.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 25.53% and a net margin of 23.15%.

A number of other analysts have also commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of ResMed in a research report on Friday, October 25th. Stifel Nicolaus assumed coverage on ResMed in a report on Friday, December 13th. They set a “hold” rating and a $250.00 price objective for the company. StockNews.com upgraded ResMed from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. The Goldman Sachs Group began coverage on shares of ResMed in a research note on Thursday, January 16th. They set a “buy” rating for the company. Finally, Robert W. Baird lifted their price objective on shares of ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a report on Friday, October 25th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $238.40.

ResMed Stock Up 1.9 %

Shares of NYSE RMD opened at $257.63 on Friday. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The firm has a market cap of $37.82 billion, a PE ratio of 34.12, a P/E/G ratio of 1.83 and a beta of 0.70. The company’s fifty day simple moving average is $240.04 and its 200 day simple moving average is $235.84. ResMed has a 12-month low of $170.56 and a 12-month high of $263.05.

Institutional Trading of ResMed

A number of institutional investors have recently added to or reduced their stakes in RMD. True Wealth Design LLC lifted its holdings in shares of ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 110 shares in the last quarter. Ashton Thomas Securities LLC purchased a new position in shares of ResMed during the 3rd quarter valued at $34,000. Rosenberg Matthew Hamilton purchased a new stake in shares of ResMed in the fourth quarter worth $54,000. Capital Performance Advisors LLP bought a new position in ResMed in the 3rd quarter worth about $60,000. Finally, Quarry LP raised its holdings in shares of ResMed by 271.9% in the 2nd quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock valued at $63,000 after acquiring an additional 242 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insiders Place Their Bets

In other ResMed news, Director Witte Jan De sold 796 shares of the business’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total value of $198,052.76. Following the sale, the director now directly owns 6,723 shares in the company, valued at $1,672,749.63. The trade was a 10.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Justin Leong sold 6,160 shares of ResMed stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $243.09, for a total value of $1,497,434.40. Following the completion of the sale, the insider now directly owns 21,718 shares of the company’s stock, valued at approximately $5,279,428.62. This trade represents a 22.10 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 11,030 shares of company stock valued at $2,702,687. Company insiders own 0.71% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.